Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Gossamer regains worldwide seralutinib rights and control across PAH, PH-ILD, and potential future indications.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Gossamer regains worldwide seralutinib rights and control across PAH, PH-ILD, and potential future indications
- Chiesi to pay Gossamer $5 million within 10 days for outstanding development costs
- Gossamer assumes success-based milestone payments and capped royalties on net sales of previously licensed products
- Chiesi transfers related regulatory filings and intellectual property, with licenses revocable after uncured payment breaches
- Agreement terminates the 2024 collaboration, preserves indemnities, and releases most legacy claims
Item 2.02 · Results of Operations and Financial Condition
- Preliminary liquidity of approximately $57.0 million at June 30, 2026
- Cash balance includes cash, cash equivalents, and marketable securities
- Unaudited estimate remains subject to quarter-end closing adjustments
- Limited liquidity visibility pending finalized June 30, 2026 financial statements
Item 7.01 · Regulation FD Disclosure
- Gossamer Bio announced rights reacquisition and related license termination, signaling a material shift in its partnering strategy
- Press release includes FDA regulatory and business updates relevant to development timelines and commercialization prospects
- Full details are in Exhibit 99.1, covering the July 27, 2026 announcement
Item 8.01 · Other Events
- Seralutinib NDA submission planned for September 2026 following FDA Type B meeting
- FDA classified PROSERA statistical significance and treatment-effect magnitude as review issues, not filing issues
- NDA strategy relies on Phase 3 PROSERA, Phase 2 TORREY, and supportive analyses
- Potential FDA approval decision in Q3 2027 if the NDA is accepted for filing
- FDA approvability remains uncertain pending review of the complete NDA
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.